Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

BACKGROUND: Combination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian cancer (ROC). We report the results of camrelizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Lingfang, Peng, Jin, Lou, Ge, Pan, Mei, Zhou, Qi, Hu, Wenjing, Shi, Huirong, Wang, Li, Gao, Yunong, Zhu, Jianqing, Zhang, Yu, Sun, Rong, Zhou, Xianfeng, Wang, Quanren, Wu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753451/
https://www.ncbi.nlm.nih.gov/pubmed/35017154
http://dx.doi.org/10.1136/jitc-2021-003831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753451/
https://www.ncbi.nlm.nih.gov/pubmed/35017154
http://dx.doi.org/10.1136/jitc-2021-003831

Ejemplares similares